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Autoimmune phenomena are more frequent in thymic epithelial tumors (TET) than in any other
human tumor. Mysthenia gravis (MG) is by far the most common autoimmune disease in
thymoma patients. MG is characterized by muscle weakness due to autoantibodies against the
acetylcholine receptor (AChR), and CD4 AChR-specific T cells play a pivotal role for the
production of these autoantibodies. About 10% of MG patients have a thymoma and,
interestingly, only such thymomas exhibit an MG association that maintains thymuslike
morphological and functional features with respect to the homing and differentiation of immature
T cells. Since AChR protein is not expressed in thymomas, the specificity of the autoimmunity
in thymoma-associated MG is thought to be determined by nonreceptor proteins with AChR
epitopes. Such proteins are overexpressed in cortical-type MG-associated thymomas, and
medullary thymomas express these proteins at barely detectable levels. Aside from this
quantitative difference, the pathogenesis of anti-AChR autoimmunity might be qualitatively
different in these thymoma subtypes. Our findings suggest that an antigen-specific abnormal T-
cell selection,by cortical-type TET may contribute to the pathogenesis of paraneoplastic MG. In
contrast, an abnormal (intratumorous) activation of autoreactive T cells may be operative in
medullary thymomas.
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Classification Categories Abbreviations
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INTRODUCTION
Thymus tumors can be histologically divided into
thymic epithelial tumors (TET, including thymomas
and thymic carcinoms), lymphomas, thymic germ-cell
tumors, and mesenchymal neoplasms (Mtiller-Herme-
link et al., 1996). Strikingly, paraneoplastic autoim-
*Corresponding author.
munity is a feature only of TET (Miiller-Hermelink,
1997). Among TET, organotypic and nonorganotypic
TET can be distinguished (Kirchner et al., 1992).
Organotypic TET are benign or malignant epithelial
neoplasms that retain functional properties of the
normal thymus with respect to the homing and
maturation of immature thymocytes (Kirchner et al,
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TABLE Frequency of MG and Expression of the AChR Epitope Alpha 373-380 in Thymic Epithelial Tumors (TET) Investigated
Between 1970 and 1994 in the Department of Pathology, University of Wtirzburg
Tumor Cases investigated Frequency of MG(%) Tumors with a 373-380b Tumors without a 373-380b
Organotypic TET
Medullary thymoma 10 30
Mixed thymoma 33 40
Predominantly 15 40
coritical thymoma
Cortical thymoma 81 69
Well-differentiated 33 79
thymic carcinoma
Nonorganotypic TET 24 0
Tumors with MG
Tumors without MG
0 3
14
6 5
14
11 0
2
30 8
4 16
aAll cases available (frozen and paraffin).
bCases with available frozen material (allowing reactivity with mAb 155 against the AChR alpha 373-380 epitope).
TABLE II Presumed Autoimmune Diseases and Immunological Systemic Disorders Observed in Association with Thymoma and MG
Pure red-cell aplasia; Hypogammaglobulinemia; white blood cells aplasia; autoimmune hemolytic anaemia
Grave’s disease (Morbus Basedow), Hashimoto thyroiditis
Lupus erythematodes, rheumatoid arthritis, polymyositis, Sj6gren’s disease
Subacute motor neuropathy
Vitiligo, alopecia areata, bullous dermatoses
Wegener’s granulomatosis, Crohn’s disease, Sarcoidosis
Sources: aRosai, 1996; Marx et al., 1996ab; and Andonopoulos et al., 1991.
bOut own observations.
1992; Mtiller-Hermelink, 1996, 1997). In addition,
organotypic TET are divided into medullary, mixed,
predominantly cortical (organoid), and cortical thy-
momas and well-differentiated thymic carcinomas
based on the morphological resemblance of neoplastic
epithelial cells to the normal thymic epithelial-cell
subtypes (Mtiller-Hermelink et al., 1996). The occur-
rence of paraneoplastic autoimmunity is restricted to
organotypic TET apart from very rare exceptions
(Rosai, 1996, Mtiller-Hermelink et al., 1996; Marx
et al., 1996a). In contrast, nonorganotypic TET
(squamous cell carcinomas, lympho-epitheliomalike
carcinomas, clear-cell carcinomas, mucoepidermoid
carcinomas, carcinoids, small-cell carcinomas, sarco-
matoid carcinomas, or papillary adenocarcinomas)
resemble their nonthymic counterparts in other organs
and are not associated with paraneoplastic autoim-
munity. This is particularly true for myasthenia gravis
(MG) (Table I). Only acquired neuromyotonia, which
is elicited by autoantibodies against he voltage-gated
potassium channel may be an exception to this rule
(Vincent et al., 1995) since it was found to be
associated with thymic carcinoids that are considered
nonorganotypic TET (Mtiller-Hermelink, 1996).
The list of autoimmune diseases associated with
TET is remarkably long (Table II). While MG,
hypoglobulinemias, pure red-cell aplasia, and other
cytopenias occur frequently enough to suggest a
pathogenetic role of the TET, this is less certain in the
other autoimmune diseases in which TET are rare
exceptions. Therefore, it has been suggested that
thymomas may trigger either a specific defect of
immune tolerance (in the case of MG and the
cytopenias) or a general disturbance of immune
regulation. This notion is supported by the finding that
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TABLE III MG Subtypes According to Thymus Pathology: Correlation with Clinical and Epidemiological Findings. MG with Neither
Thymitis nor TET Exhibits an Age-Related thymus ("atrophy").
Thymus pathology Thymitis "Hyperplasia" Thymoma/WDTC
Onset of symptoms age (years) 10-20 15-80
Sex m:f 1:3 1:1
HLA association B8; DR3 (DR2)
Autoantibodies against
AchR 30-80% >90%
striated muscle 10-20% >90%
titin <5% >90%
neuronal structures <10% >90%
ryanodine receptor <5% >50%
Effect of thymectomy Improvement in 80% Deterioration in 80%
Sources: See Marx et al., 1996a; Mygland et al., 1994, 1997.
aWDTC: well-differentiated thymic carcinoma; Kirchner et al., 1992.
almost exclusively occur in medullary thymomas
whereas MG is mainly associated with cortical-type
TET (Rosai, 1996; Mtiller-Hermelink et al., 1996).
Investigations concerning the pathogenetic links
between TET and paraneoplastic autoimmunity have
been hampered because of the rarity of almost all
autoimmune diseases listed in Table II. This is not the
case for paraneoplastic MG. Therefore, paraneo-
plastic MG serves as a model for the analysis of the
relationship between functional properties and
morphological features of the tumor, and the develop-
ment of autoimmunity. In this paper, we will
summarize clinical and pathological features of MG-
associated TET and discuss novel findings for both
the epithelial and lymphoid compartments of these
neoplasms.
RESULTS
Clinical and Epidemiological Findings in
Paraneoplastic Myasthenia Gravis
Myasthenia gravis (MG) is an autoimmune disease
characterized by an autoantibody attack against the
AChR at the neuromuscular junction. However, the
disease is not defined by the presence of auto-
antibodies, but by the abnormal weakness of striated
muscles after contraction and by characteristic elec-
trophysiological features (Drachman, 1994). Except
for this common clinical denominator, MG is a
heterogeneous group of diseases. Since clinical and
epidemiological findings exhibit a high association
with characteristic thymic abnormalities, it has
become common practice to subdivide MG according
to the associated pathological thymic alterations
(Table III).
It is significant for the pathogenesis of paraneo-
plastic MG that there is no age and gender predilec-
tion and almost no HLA association in paraneoplastic
MG as opposed to the more frequent MG type that
occurs in thymitis (Table III).
Whereas MG in thymitis patients is characterized
by autoimmunity almost exclusively against the
AChR, paraneoplastic MG is distinguished by a range
of additional autoantibodies against striated muscle
antigens (actin, myosin, actinin, ryanodine receptor,
and titin) and against neuronal structures (Williams et
al., 1992; Aarli et al., 1990; Marx et al., 1992; Gautel
et al., 1993; Mygland et al., 1994). Finally, surgery
has strikingly contrary effects on the autoimmune
symptoms in MG with thymitis compared with
thymoma-associated MG (Table III). These findings
clearly separate paraneoplastic MG from nonparaneo-
plastic MG cases.
Most Autoantigens Are not Expressed in MG-
Associated Thymic Epithelial Tumors but
Autoantigen Epitopes Are
To explain the unique pattern of autoimmunity
against the AChR, titin, and the ryanodine receptor,132 A. MARX et al.
TABLE IV Expression of Autoantigen Epitopes but Not of the Main Antigens Themselves in Myasthenia Gravis-Associated
Thymoma
Autoantigen Autoantigen expression Expression of autoantigen epitope
AChR No Yes
Titin No Yes
Ryanodine receptors No Yes
one has looked for the occurrence of these autoanti-
gens in MG-associated thymomas. Although, mRNA
for the AChR subunits has been detected by RT-PCR
(Hara et al., 1991, 1993) and by screening of
thymoma cDNA libraries (Gattenl6hner et al., 1994),
AChR, titin, and ryanodine receptors have not been
identified on the protein level (Kirchner et al., 1988b,
Siara et al., 1991, Mygland et al., 1997, Wilisch et al.,
1997). Instead, by using panels of monoclonal
antibodies against these various autoantigens, single
cross-reacting epitopes could be recognized with
monoclonal antibodies against the AChR (Kirchner et
al, 1988b; Wilisch et al., 1997), the ryanodine
receptor (Mygland, 1997), and against titin (Marx,
1996a b) (Table IV). The only exception to the rule
has been paraneoplastic antineuronal autoimmunity in
thymoma/MG patients (Marx et al., 1992). This type
of autoimmunity is partially due to autoantibodies
against neurofilaments (unpublished). As shown
recently, antineuronal autoimmunity is associated
with the intratumorous expression not only of single
epitopes but complete neurofilament proteins that are
abnormal only due to their incomplete state of
phosphorylation (Marx et al., 1996b).
A Single Thymoma Molecule Contains Epitopes
of Three Main Autoantiges
It has remained enigmatic until recently why thymo-
mas in paraneoplastic MG should elicit autoimmunity
against apparently unrelated molecules (AChR, titin,
neuronal structures) at an almost identical frequency
(Table I). However, when neurofilaments were identi-
fied in MG-associated thymomas, it became clear that
the 160-kD neurofilament contains titin epitopes
(Marx et al., 1996b) as well as epitopes homologous
to the AChR epitope alpha 373-380 (Wilisch et al.,
1997). Therefore, we suggest that the abnormal
expression of a single molecule containing epitopes of
the three most frequent autoantigens may be the
reason for the simultaneous appearance of the three
types of autoimmunity (Fig. 1). Whether neurofila-
ments also contain a ryanodine receptor epitope
remains to be shown.
Loss ofTolerance
in
Paraneoplastic Myasthenia
/ ",,
Neurofilament NF-M
(AChR, Titin, and Neuronal Epitopes)
Abnormal Selection ? Abnormal Activation ?
FIGURE Hypotheses to explain the restricted autoimmune response against the AChR, titin, and neuronal structures regarding the fact
that neither AChR nor titin are expressed in MG-associated thymic epithelial tumors. Cross-reacting epitopes of the AChR and titin occurring
in the abnormally expressed 160-kD neurofilament (NFM) might elicit T-cell autoreactivity either by abnormal selection or an abnormal
stimulation of T cells.PARANEOPLASTIC MYASTHENIA GRAVIS 133
The Expression of AChR Epitopes is Correlated
with the Occurrence ofMG in Thymic Epithelial
Tumors
As shown in Table I, the occurrence ofMG is clearly
associated with the expression of the AChR alpha
subunit epitope alpha 373-380 (Kirchner et al., 1988a,
1988b; Marx et al., 1996a). This association is most
striking in cortical-type thymomas. In this subtype,
the patients never suffer from MG when this epitope
is not expressed (n 5; unpublished). The absent or
low expression of this AChR epitope in medullary
and mixed thymomas may be one reason why
paraneoplastic MG is rare in these tumors (Table I). It
has been suggested that MG in these TET subtypes
may be related to other so far unknown cross-reacting
epitopes or a different pathogenetic mechanism
(Nenninger et al., 1996).
Increased Frequency of Autoantigen Reactive T
Cells in MG-Associated Thymic Epithelial
Tumors
To investigate the relevance of the abnormal neu-
rofilamen expression in MG-associated TET, we
looked for the occurrence ofAChR and neurofilament
reactive T cells in thymic epithelial tumors. As shown
in Fig. 2, T cells reacting with a recombinant
neurofilament fragment and various AChR fragments
were more frequently encountered in thymomas than
AChR-and Neurofilament-induced Proliferation of
Thymocytes from Thymus and Thymoma
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FIGURE 2 Increased frequency ofAChR and neurofilament reactive T cells in thymomas. Proliferation of thymocytes from normal thymuses
(n 6) and mixed and cortical-type thymomas (n 10) in response to the recombinant human neurofilament fragment aa459-737 (NF-M) and
various recombinant fragments and peptides of the AChR alpha subunit. Proliferation was measured by 3H-thymidine incorporation and is
given as the stimulation index (SI). Each + represents the mean of six wells per patient and antigen with 5 104 cells/well.134 A. MARX et al.
in the normal thymus. These findings are in line with
those reported by Sommer et al. (1990) for AChR-
reactive T cells. Like these authors, we were not able
to raise T-cell responses against the AChR epitope
alpha 373-380 (Fig. 2). Nevertheless, these findings
show that abnormal antigen expression in thymomas
may not elicit tolerance butmsurprisingly--the pro-
duction/accumulation of T cells reactive against these
antigens.
ICAM-1
Abnormal Stimulation vs. Abnormal Selection
Inside MG-Associated Thymic Epithelial
Tumors?
It has been a major controversy whether TET elicit
autoimmunity by the intratumorous stimulation of
members of the normal T-cell repertoire (Sommer et
al., 1990, Willcox, 1993) or an abnormal intra-
tumorous T-cell selection is the main pathogenetic
contribution of MG-associated TET (Fig. 1) (Marx et
al., 1991; Mtiller-Hermelink et al., 1996; Wilisch et
al., 1997). To substantiate the "abnormal selection
hypothesis," we first confirmed that mixed and
cortical thymomas and well-differentiated thymic
carcinomas indeed support T-cell maturation from the
earliest intrathymic precursors to the most mature T-
cell subset (Nenninger et al., 1996). Furthermore, we
investigated the expression of activation markers on
CD4+/CD3 mature T cells by flow cytometry.
However, neither an early (ICAM-1; Fig. 3) nor a late
activation antigen (CD25; not shown) could be
detected in the mature CD4 T-cell compartment in
over 90% of cases. This finding was confirmed when
the sensitivity of the method was increased 10- to
20-fold by depleting CD8 and CD4/CD8 cells from
the TET thymocytes prior to ICAM-1 and CD25 flow
cytometry (unpublished). Although it was shown
previously that cortical-type neoplastic thymic epi-
thelial cells have the abnormal capacity to present
soluble antigen to mature T cells in vitro (Marx et al.,
1994; Gilhus et al., 1995), the ex vivo experiments
described here favor the hypothesis that thymoma
tissue in the majority of cases does not stimulate
intratumorous autoreactive T cells in vivo.
normal thymus
8%
thymitis
thymoma
O%
FIGURE 3 Absence of the early activation marker ICAM1 from
CD4+/CD3 T cells derived from an MG-associated cortical
thymoma. For comparison, an increased number of activated T cells
is detectable in thymoytes from thymitis as compared to the normal
thymus. The histogram shown is representative for three other
cortical thymomas and three mixed thymomas investigated in the
same way by flow cytometry. A similar finding was obtained with
an antibody to the late activation antigen CD25 (not shown).PARANEOPLASTIC MYASTHENIA GRAVIS 135
Thymomas Provide Immunosuppression in
Paraneoplastic MG
TET are unique among tumors associated with
paraneoplastic autoimmunity since TET surgery is
followed by a deterioration of autoimmunity disease
symptoms and rising autoantibody titers (Somnier,
1994; Nix et al., 1997; Schalke et al., 1997) (Fig. 4a).
To investigate the biological basis of this phenome-
non at a cellular level, we checked for the frequency
of AChR-reactive T cells in the peripheral blood of
thymoma patients at the time of surgery and 1 week
later. As shown in Fig. 4b, the number of autoreactive
T cells in the peripheral blood increased 1 week after
surgery in thymoma patients, whereas the opposite
was true in MG patients with thymitis. These findings
show that MG-associated TET exert an immuno-
suppressive effect not only with respect to auto-
antibodies (Fig. 5a), but also against antigen-specific
T cells (Fig. 4b). The longer-term fate of patients
following surgery with respect to the levels of
autoreactive T cells in the blood has yet to be
evaluated.
DISCUSSION
The key features of MG-associated cortical type TET
are as follows: (1) The maintenance of thymuslike
functional properties with respect to the homing and
maturation of immature T cells. (2) The abnormal
expression of cross-reacting AChR, titin, ryanodine
receptor, and neuronal epitopes by the neoplastic
epithelial cells in a cortical-type microenvironment.
(3) The increased number of intratumorous autor-
eactive T cells against these autoantigens (as shown
for the AChR and neurofilaments). (4) The apparent
absence of activated intratumorous CD4 T cells.
The latter two features taken together suggest that
the increased number of autoreactive intratumorous T
cells results mainly from the preferential intra-
tumorous production/selection of autoreactive T cells
(Marx et al., 1991). As an alternative possibility,
enrichment of MG-associated TET in autoaggressive
T cells by T cell recirculation has been suggested
(Sommer et al., 1990). In fact, recirculation of mature
T cells into nonneoplastic thymic tissue in various
species is preferentially achieved by activated but
much less so by naive T cells (Surh et al., 1993).
Nevertheless, we consider this an unlikely possibility
to explain the high number of autoaggressive T cells
in thymomas. In support of this hypothesis and using
tetanus-toxin-specific T-cell proliferation as readout,
we found recently that mature T cells recirculate
regularly into the normal thymus (including residual
thymic tissue adjacent to thymomas) but almost never
into thymomas (unpublished).
Considering the high association between abnor-
mally expressed autoantigen epitopes (Table I) in
MG-associated TET, we further suggest that the
increased production of antigen-specific T cells might
result from the presentation of cross-reacting peptides
in MHC class II molecules on neoplastic thymic
epithelial cells. Obviously, such abnormally selected
autoreactive T cells have to be exported to the
extratumorous lymphoid tissues in order to become
activated and provide help to autoaggressive B cells
producing autoantibodies.
In our opinion, all the features outlined so far can
best be reconciled with a two-stage model, as given in
Fig. 5. According to this model, the MG-associated
TET provide an increased number of autoreactive
naive T cells, and on the second stage, these T cells
are activated in the extratumorous "periphery." The
"periphery" can be clearly the residual thymus close
to the TET since we could detect a high number of
antigen-specific T cells there (unpublished). How-
ever, other lymphoid organs and probably the bone
marrow also have to play a role in this process,
because extended thymomectomy (including the
residual thymus) is not followed by a decline but by
an increase of autoantibody titers instead (Fig. 4a). It
has not been elucidated which autoantigen(s) are
maintaining this prolonged autoimmune reaction
although the AChR itself is an obvious candidate.
Regardless whether one favors the "abnormal selec-
tion" or "abnormal stimulation" hypothesis, it has
remained enigmatic how the intrathymomatous
expression of single cross-reacting epitopes of the
AChR, titin, and the ryanodine receptor might elicit
(or stimulate) intratumorous antigen-specific T cells136 A. MARX et al.
Thymoma-mediated Immunosuppression in Paraneoplastic MG
a) Immunosuppressive Effects on Autoantibodies
Auto-Ab titer
Start of tumor
development
AUTOIMMUNITY ?
Surgery
Thymoma
Thymitis
AUTOIMMUNE DISEASE
b) Immunosuppressive Effects on AChR- and NF-reactive T cells
Percentage of positive T cell proliferation assays
immediately
after surgery
7 days
after surgery
Thymoma 29% 49%
Thymitis 34% 29%
FIGURE 4 (a) Opposite effect of thymectomy and tumor surgery on the autoantibody titer in patients with MG-associated thymitis (dashed
curve) and thymoma (solid curve). The rise in autoantibody titer is usually accompanied by deterioration of the clinical state (Somnier, 1994;
Nix et al., 1997; Schalke et al., 1997). (b) Increased frequency of AChR and neurofilament-reactive T cells in the peripheral blood week
after surgery in MG patients with mixed and cortical thymoma (n 9). The figures given indicate the percentage of positive wells detected
in antigen-specific T-cell proliferation assays, combining all assays with the stimulating autoantigen fragments given in Fig. 2. By contrast,
the frequency of autoreactive T cells in patients with thymitis declines slightly after surgery.PARANEOPLASTIC MYASTHENIA GRAVIS 137
that we (Fig. 2) and others (Sommer et al., 1990) have
shown to recognize a broad spectrum of autoantigen
epitopes (including cytoplasmic sequences).
Future experiments will have to show whether
further cross-reacting epitopes occur inside TET.
Another apparent paradox is the finding that
expression of the AChR epitope alpha 373-380 in
TET is clearly associated with anti-AChR autoim-
munity, but that AChR alpha 373-380 peptide-specific
T cells have not been detected in MG/thymoma
patients (Fig. 2). According to the pathogenetic model
suggested in Fig. 5, we favor the view that the peptide
homologues of alpha 373-380 in neoplastic epithelial
cells could function as selecting peptides for imma-
ture thymocytes (Marx et al., 1991). In this case, one
would in fact predict that mature T cells might not
respond to these abnormally expressed peptides
because selecting peptides in the thymus is known to
be nonstimulatory or even antagonistic for mature T
cells outside the thymus (Ashton-Rickardt and Tone-
gawa, 1994; Hogguist et al., 1994). This hypothesis is
presently under investigation.
The pathogenesis of paraneoplastic MG in medul-
lary thymomas might be different from that in
cortical-type TET given the fact that abnormally
expressed, cross-reacting autoantigen epitopes have
not been detected in the former so far (Marx et al.,
1996a; Mtiller-Hermelink et al., 1996). In addition,
we found a substantial number ofICAM-1 and CD25-
positive, activated T cells by FACS analysis in a case
Pathogenesis of Paraneoplastic MG in Thymoma Patients
Thvm0ma Peril)herr*
abnormal Selection
Ti Tmln
Neoplastic Epithelial Cells
Abnormal AChR und Titin Epitopes
; Tm/a
IDC
Trigger
(Etiology ?)
Ab to AChR, Titin
*Residual Thymus, Lymphoid Organs, Bone Marrow
FIGURE 5 Pathogenesis of paraneoplastic MG in thymoma patients. According to this "two-step model," abnormal AChR and titin
epitopes provide the molecular basis for an abnormal intratumorous selection that turns immature T cells (Ti) into mature and native T cells
(Tnvn). In a second step, these AChR and titin-specific T cells are thought to leave the thymus and become actived T cells (Ta) only outside
the tumor. The etiology-triggering T-cell activation is unknown (Vincent, 1994).138 A. MARX et al.
of MG-associated medullary thymoma (Nenninger et
al., 1996). Whether these findings indeed indicate an
intratumorous activation of autoantigen-specific T
cells has to be substantiated by functional investiga-
tions in a larger series of medullary thymomas.
Another major finding in our studies is the
detection of an immunosuppressive effect of TET on
AChR and neurofilament reactive T cells in patients
with paraneoplastic MG. As shown in Fig. 4, the
clinical deterioration of MG symptoms and autoanti-
body titers is accompanied by an augmented antigen-
specific T-cell response. Whether this immuno-
suppressive effect of TET is exerted by soluble
factors (e.g., IL-10 or TGF-/3) or by antigen-specific
suppressor T cells has not definitely been shown.
However, we have preliminary evidence that antigen-
specific suppressive mechanisms are indeed effective,
which has important implications for future immuno-
therapeutic strategies.
Biochemical and Molecular Biological
Techniques
The detection of neurofilament mRNA by RT-PCR
and of neurofilament proteins by Western blotting
were described recently (Marx et al., 1996b). Detec-
tion of titin and AChR epitopes in neurofilaments was
achieved using recombinantly produced neurofila-
ment fragment NF-M aa459-737 for Western blotting
applying mAb 155 and the anti-titin mAb 63/15
(Wilisch et al., 1997).
Flow Cytometry
Three-color FACS analyses on a Becton-Dickinson
FACS scan was performed as described previously
(Nenninger et al., 1996).
T-Cell Proliferation Assay
MATERIALS AND METHODS
Patients and Tissues
The clinical data of patients with paraneoplastic MG
and the histological findings of their TET summarized
in this paper have been published previously (Kirch-
ner et al., 1992; Mtiller-Hermelink et al., 1996; Marx
et al., 1996a; Nenninger et al., 1996). Normal
thymuses were obtained during thoracic surgery.
Tumors were classified according to Mtiller-Herme-
link and co-workers (1996, 1997). The diagnosis of
generalized MG was based on clinical findings,
electrophysiological investigations, and anti-AChR
serum titers that were >1 nmol/1.
The T-cell proliferation assay using density-gradient-
enriched cell suspensions from minced thymoma or
nonneoplastic thymic tissue or peripheral blood
mononuclear cells were performed as described by
Melms et al. (1992). Since density-gradient-enriched
thymoma-cell suspensions (and to a smaller extent
thymus-cell suspensions) were found to exhibit a
suboptimal antigen-presenting capacity, 5 104
responder cells from thymoma and thymus samples
were supplemented with 105 irradiated (50 Gy)
peripheral blood mononuclear cells for improved
antigen presentation (unpublished). Antigens used in
proliferation assays were supplied at optimal concen-
trations (peptides, 10 /g/ml; recombinant protein
fragments, 1 /zg/ml).
Immunohistochemistry
The application of the anti-AChR monoclonal anti-
body (mAb) 155 and of the various anti-neurofilament
and anti-titin mAb in a three-step immunoperoxidase
staining has been described previously (Kirchner et
al., 1988b; 1992; Marx et al., 1996b).
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